肺动脉高压（PAH）是一种危害严重的心肺疾病，它的特点在于病情会逐渐加重，伴随着明显的症状，并且在病情持续发展下可能会致命。PAH的主要病理特征是肺动脉的结构发生改变，同时血液循环的动力学也出现异常。尽管在过去十年中，PAH的治疗取得了显著进展，但诊断延迟和治疗效果不理想仍然是实现最佳结果的主要障碍。PAH的发病机制复杂，涉及多种病理生理过程，其中炎症和代谢紊乱的作用逐渐受到关注。

Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

Seropositive rheumatoid arthritis may be protective against the development of PAH, based on results of Mendelian randomization analyses.

Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...

11, 2024 — A drug approved to treat pulmonary arterial hypertension may be effective at managing hypertension and end-organ damage in patients with sickle cell disease, according to a new study.

Natco Pharma gains FDA approval for generic Bosentan tablets, partnering with Lupin Pharmaceuticals for U.S. marketing.

Women are more likely to have pulmonary arterial hypertension, but men tend to have worse outcomes and worse treatment responses.

Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta: Shardul Nautiyal, Mumbai Saturday, February 8, 2025, 08:00 Hrs [IST] Dr Ma ...

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...